Heparin and Cancer
From: H:S Bispebjerg Hospital, Kirurgisk Gastroenterologisk Afdeling K, København NV. jly@dadlnet.dk
Ugeskrift for laeger
- Publish Date: Dec 2006
- ISSN: 1603-6824
- Volume: 168
- Issue: 50
- Pages: 4397-401
- Medium: Internet
- Language:
- Citation (JAMA): Lykke Jakob, et al. Heparin and Cancer. Ugeskr. Laeg. Dec 2006;168:4397-401
Abstract
The association between cancer and venous thromboembolism is well described. Several studies indicate that elements of the haemostatic system participate in tumour genesis. During the last decade a number of post-hoc analyses of trials not primarily designed to evaluate the effect of low molecular weight heparins (LMWH), on cancer survival, have indicated an increased survival. This has recently been supported by results from several prospective trials with LMWH. The possible anti-cancer effect of LMWH is not known in details. Treatment regimes with LMWH have to be performed.
Mesh Headings (Keywords): Anticoagulants, Fibrinolytic Agents, Heparin, Low-Molecular-Weight, Humans, Neoplasms, Risk Factors, Survival Rate, Thromboembolism, Venous Thrombosis
Check for Full Text / PubMed Unique Identifier (PMID): 17217864
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.